126 related articles for article (PubMed ID: 34423592)
21. Cell cycle progression score improves risk stratification in prostate cancer patients with adverse pathology after radical prostatectomy.
Shangguan X; Qian H; Jiang Z; Xin Z; Pan J; Dong B; Xue W
J Cancer Res Clin Oncol; 2020 Mar; 146(3):687-694. PubMed ID: 31745702
[TBL] [Abstract][Full Text] [Related]
22. Transurethral resection of the prostate is an independent risk factor for biochemical recurrence after radical prostatectomy for prostate cancer.
Jin K; Qiu S; Liao XY; Zheng XN; Tu X; Tang LS; Yang L; Wei Q
Asian J Androl; 2020; 22(2):217-221. PubMed ID: 31210148
[TBL] [Abstract][Full Text] [Related]
23. Identification of men with low-risk biopsy-confirmed prostate cancer as candidates for active surveillance.
Lin DW; Crawford ED; Keane T; Evans B; Reid J; Rajamani S; Brown K; Gutin A; Tward J; Scardino P; Brawer M; Stone S; Cuzick J
Urol Oncol; 2018 Jun; 36(6):310.e7-310.e13. PubMed ID: 29655620
[TBL] [Abstract][Full Text] [Related]
24. Validation of the Combined Clinical Cell-Cycle Risk Score to Prognosticate Early Prostate Cancer Metastasis From Biopsy Specimens and Comparison With Other Routinely Used Risk Classifiers.
Hutten RJ; Odei B; Johnson SB; Tward JD
JCO Precis Oncol; 2024 Feb; 8():e2300364. PubMed ID: 38330260
[TBL] [Abstract][Full Text] [Related]
25. Local progression among men with conservatively treated localized prostate cancer: results from the Transatlantic Prostate Group.
Eastham JA; Kattan MW; Fearn P; Fisher G; Berney DM; Oliver T; Foster CS; Møller H; Reuter V; Cuzick J; Scardino P;
Eur Urol; 2008 Feb; 53(2):347-54. PubMed ID: 17544572
[TBL] [Abstract][Full Text] [Related]
26. Prognostic value of Ki-67 for prostate cancer death in a conservatively managed cohort.
Fisher G; Yang ZH; Kudahetti S; Møller H; Scardino P; Cuzick J; Berney DM;
Br J Cancer; 2013 Feb; 108(2):271-7. PubMed ID: 23329234
[TBL] [Abstract][Full Text] [Related]
27. Are transrectal prostate biopsies routinely indicated in patients with incidentally diagnosed prostate cancer following transurethral resection of the prostate for benign disease?
Lee LS; Thiruneelakandasivam S; Hong MK; Peters JS; Warren A; Mills R; Greenberg D; Wright K; Gnanapragasam V
Urol Int; 2013; 91(4):397-403. PubMed ID: 23921216
[TBL] [Abstract][Full Text] [Related]
28. The diagnostic value of prostate cancer between holmium laser enucleation of the prostate and transurethral resection of the prostate for benign prostatic hyperplasia: A retrospective comparative study.
He G; Sun C; Shu Y; Wang B; Du C; Chen J; Wen J
Int J Surg; 2020 Jul; 79():217-221. PubMed ID: 32447004
[TBL] [Abstract][Full Text] [Related]
29. Improving risk stratification in a community-based African American population using cell cycle progression score.
Rayford W; Greenberger M; Bradley RV
Transl Androl Urol; 2018 Sep; 7(Suppl 4):S384-S391. PubMed ID: 30363476
[TBL] [Abstract][Full Text] [Related]
30. Incidentally Detected Adenocarcinoma Prostate in Transurethral Resection of Prostate Specimens: a Hospital Based Study from India.
Varghese J; Kuruvilla PM; Mehta N; Rathore RS; Babu M; Bansal D; Pillai B; Sam MP; Krishnamorthy H
Asian Pac J Cancer Prev; 2016; 17(4):2255-8. PubMed ID: 27221926
[TBL] [Abstract][Full Text] [Related]
31. Prognostic utility of the cell cycle progression score generated from biopsy in men treated with prostatectomy.
Bishoff JT; Freedland SJ; Gerber L; Tennstedt P; Reid J; Welbourn W; Graefen M; Sangale Z; Tikishvili E; Park J; Younus A; Gutin A; Lanchbury JS; Sauter G; Brawer M; Stone S; Schlomm T
J Urol; 2014 Aug; 192(2):409-14. PubMed ID: 24508632
[TBL] [Abstract][Full Text] [Related]
32. Diagnosis of prostate cancer: repeated transrectal prostate biopsy or transurethral resection.
Lin CC; Huang WJ; Wu LJ; Chang YH; Lin AT; Chen KK
J Chin Med Assoc; 2008 Sep; 71(9):448-54. PubMed ID: 18818137
[TBL] [Abstract][Full Text] [Related]
33. Prevalence and risk factors for incidental prostate cancer in patients after transurethral resection of the prostate with negative results on prostate biopsy: A retrospective study.
Guo Z; He J; Pan J; Huang L; Cao J; Bai Z; Wang S; Xiang S; Gu C; Wang Z
Investig Clin Urol; 2022 Mar; 63(2):201-206. PubMed ID: 35244994
[TBL] [Abstract][Full Text] [Related]
34. Comparison of transrectal ultrasound-guided biopsy of the prostate and transurethral resection of the prostate for detection of prostate cancer in patients with moderate lower urinary tract symptoms.
Chen SS; Chiu LP; Chen KK
J Chin Med Assoc; 2010 Nov; 73(11):568-72. PubMed ID: 21093824
[TBL] [Abstract][Full Text] [Related]
35. The prognostic significance of combined ERG and androgen receptor expression in patients with prostate cancer managed by androgen deprivation therapy.
Huang KC; Alshalalfa M; Hegazy SA; Dolph M; Donnelly B; Bismar TA
Cancer Biol Ther; 2014 Sep; 15(9):1120-8. PubMed ID: 24972028
[TBL] [Abstract][Full Text] [Related]
36. "Finding the needle in a haystack": oncologic evaluation of patients treated for LUTS with holmium laser enucleation of the prostate (HoLEP) versus transurethral resection of the prostate (TURP).
Herlemann A; Wegner K; Roosen A; Buchner A; Weinhold P; Bachmann A; Stief CG; Gratzke C; Magistro G
World J Urol; 2017 Nov; 35(11):1777-1782. PubMed ID: 28516315
[TBL] [Abstract][Full Text] [Related]
37. Oncological effect of palliative transurethral resection of the prostate in patients with advanced prostate cancer: a propensity score matching study.
Choi SY; Ryu J; You D; Jeong IG; Hong JH; Ahn H; Kim CS
J Cancer Res Clin Oncol; 2018 Apr; 144(4):751-758. PubMed ID: 29417257
[TBL] [Abstract][Full Text] [Related]
38. The relationship of palliative transurethral resection of the prostate with disease progression in patients with prostate cancer.
Krupski TL; Stukenborg GJ; Moon K; Theodorescu D
BJU Int; 2010 Nov; 106(10):1477-83. PubMed ID: 20977594
[TBL] [Abstract][Full Text] [Related]
39. Cell-cycle Progression-score Might Improve the Current Risk Assessment in Newly Diagnosed Prostate Cancer Patients.
Oderda M; Cozzi G; Daniele L; Sapino A; Munegato S; Renne G; De Cobelli O; Gontero P
Urology; 2017 Apr; 102():73-78. PubMed ID: 27894974
[TBL] [Abstract][Full Text] [Related]
40. Risk assessment for prostate cancer metastasis and mortality at the time of diagnosis.
Cooperberg MR; Broering JM; Carroll PR
J Natl Cancer Inst; 2009 Jun; 101(12):878-87. PubMed ID: 19509351
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
